

**Department of Planning and Budget
2026 General Assembly Session
State Fiscal Impact Statement**

PUBLISHED: 1/26/2026 5:10 PM

ORIGINAL

Bill Number: HB917

Patron: Willett

Bill Title: Board of Pharmacy; compounding pharmacies; use of bulk drug substances; recordkeeping.

Bill Summary: Establishes additional requirements for when pharmacists may use bulk drug substances in compounding and specifies prohibitions on pharmacist use of (i) bulk drug substances that were withdrawn or removed from the market for reasons of safety and effectiveness or were covered by an investigational new drug application and not approved and (ii) compounded drug products that are essentially a copy of commercially available drug products. The bill permits the Board of Pharmacy to request records of all compounded drug products and requires pharmacists to furnish such records within 48 hours of such request or within a reasonable time as determined by the Board. The bill also permits the Board of Pharmacy to submit any information related to investigations, disciplinary proceedings, or inspection of a licensee to the National Association of Boards of Pharmacy.

Budget Amendment Necessary: No

Items Impacted: n/a

Fiscal Summary: Minimal/absorbable fiscal impact.

Fiscal Analysis: The Board of Pharmacy may perform additional audits or inspections to ensure pharmacist/licensee compliance with the provisions of this bill. This bill may also increase the amount of administrative work performed by the Board as it relates to records retention, compilation, and distribution to other parties, including the National Association of Boards of Pharmacy. It is expected that any workload or cost increases associated with the provisions of this bill can be absorbed within existing resources.

Other: n/a